北京同仁堂股份有限公司关于获得加拿大产品许可证的公告

Group 1: Product License Announcement - Beijing Tongrentang Co., Ltd. has received a Class III product license from Health Canada for its product Suhexiang Wan, allowing for potential sales in Canada [1][2] - The total research and development investment for the product by Tongrentang Pharmaceutical Factory amounts to approximately 3.05 million yuan (about 0.46 million USD) as of the announcement date [1] Group 2: Impact on Company Operations - The approval of the product license is a significant step towards market entry, but further administrative approvals, including Canadian production quality system certification, are required, which may introduce uncertainties [2] - The recent approval is not expected to have a major impact on the company's short-term operating performance [2] Group 3: Annual Shareholders Meeting Notification - The 2024 Annual Shareholders Meeting is scheduled for June 16, 2025, and will utilize a combination of on-site and online voting methods [5][6] - The meeting will take place at the company's headquarters in Beijing, with specific voting times outlined for both on-site and online participants [6][10] Group 4: Voting Procedures and Participation - Shareholders can vote through the Shanghai Stock Exchange's online voting system, with detailed instructions provided for participation [10][11] - The company aims to facilitate participation from minority investors by sending reminders and information about the meeting and voting procedures [10]